Skip to main content
Carna Biosciences, Inc. logo

Carna Biosciences, Inc. — Investor Relations & Filings

Ticker · 4572 ISIN · JP3220550002 T Manufacturing
Open in API
Filings indexed 71 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country JP Japan
Listing T 4572

About Carna Biosciences, Inc.

https://www.carnabio.com/

Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of small molecule kinase inhibitors. The company focuses on creating therapies for diseases with significant unmet medical needs, particularly in oncology and autoimmune disorders. Carna Biosciences operates through two core segments: a drug discovery business that advances its proprietary pipeline of drug candidates, and a drug discovery support business. The support division provides the global research community with a comprehensive portfolio of products and services, including a wide array of kinase proteins, biochemical and cell-based screening, and profiling services to accelerate pharmaceutical research and development.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a Japanese regulatory form (“確認書”) submitted under the Financial Instruments and Exchange Act to the Kinki Finance Bureau. It is a confirmation letter stating the proper disclosure of the company’s 23rd securities report, not the report itself. This is a compliance/regulatory filing rather than an annual report, earnings release, or proxy material. It best fits the fallback “Regulatory Filings” category (RNS).
2026-03-26 Japanese
有価証券報告書－第23期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the standard annual financial report filed with the Kinki Finance Bureau under the Financial Instruments and Exchange Act. It contains comprehensive financial statements, business indicators, and management information for the fiscal year ending December 31, 2025. This corresponds to the 10-K equivalent in the Japanese regulatory framework. FY 2025
2026-03-26 Japanese
訂正有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kinki Finance Bureau by Carna Biosciences, Inc. It details the issuance of new shares and stock acquisition rights (warrants) to specific parties. This type of filing is a regulatory document related to capital raising and share issuance, which falls under the 'Share Issue/Capital Change' category.
2026-02-10 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 1% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kinki Finance Bureau by Carna Biosciences, Inc. It details the issuance of new shares and stock acquisition rights (warrants). In the context of Japanese financial filings, this is a regulatory document related to capital raising and share issuance. Since it is a formal registration statement for a capital change/share issuance, it falls under the 'Share Issue/Capital Change' category.
2026-01-29 Japanese
訂正有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kinki Finance Bureau in Japan. It details the issuance of convertible bonds with stock acquisition rights (新株予約権付社債). This type of filing is a formal regulatory document required for public offerings or capital raising activities in Japan, which falls under the category of 'Regulatory Filings' (RNS) as it is a specific legal disclosure document that does not fit into the other specialized categories like 'Capital/Financing Update' (CAP) or 'Share Issue/Capital Change' (SHA) as defined in the provided schema, which are typically for announcements rather than formal regulatory registration statements.
2025-11-11 Japanese
訂正有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kinki Finance Bureau in Japan. It details the issuance of convertible bonds with stock acquisition rights (新株予約権付社債). This type of filing is a formal regulatory document required for capital raising activities, specifically falling under the category of share issuance and capital structure changes.
2025-09-12 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.